Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) Return on Sales (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Return on Sales for 4 consecutive years, with 5.29% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales rose 1067.0% to 5.29% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.64%, a 942.0% increase, with the full-year FY2024 number at 0.96%, up 222.0% from a year prior.
  • Return on Sales was 5.29% for Q3 2025 at 60 Degrees Pharmaceuticals, up from 17.19% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 81.53% in Q3 2023 to a low of 151.27% in Q1 2023.
  • A 4-year average of 10.16% and a median of 5.29% in 2025 define the central range for Return on Sales.
  • Biggest YoY gain for Return on Sales was 15532bps in 2024; the steepest drop was -9750bps in 2024.
  • 60 Degrees Pharmaceuticals' Return on Sales stood at 44.91% in 2022, then plummeted by -83bps to 7.64% in 2023, then soared by 188bps to 22.03% in 2024, then crashed by -124bps to 5.29% in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Return on Sales are 5.29% (Q3 2025), 17.19% (Q2 2025), and 11.48% (Q1 2025).